Evidence map›Paper›PMID 23349905›Full record

ArticlePloS one2013

RNA-Seq for enrichment and analysis of IRF5 transcript expression in SLE.

Rivka C Stone, Peicheng Du, Di Feng, Kopal Dhawan, Lars Rönnblom, Maija-Leena Eloranta, Robert Donnelly, Betsy J Barnes

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 50 citations in OpenAlex.

  1. mRNA Isoforms and Variants in Health and Disease.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Rivka C StoneDepartment of Biochemistry & Molecular Biology, New Jersey Medical School, and New Jersey Medical School-University Hospital Cancer Center, UMDNJ, Newark, New Jersey, USA.
Peicheng Du
Di Feng
Kopal Dhawan
Lars Rönnblom
Maija-Leena Eloranta
Robert Donnelly
Betsy J Barnes
Rutgers, The State University of New Jersey · USUppsala University · SENew Jersey Institute of Technology · US

Funding

ROLE OF IRF5 IN SLE PATHOGENESISR03AR054070 · NIAMS · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI BARNES, BETSY J · 2006 to 2008
$227k
NIAMS NIH HHS 5R03AR054070NIAMS NIH HHS R03 AR054070
6 · The paper itself

Abstract

Polymorphisms in the interferon regulatory factor 5 (IRF5) gene have been consistently replicated and shown to confer risk for or protection from the development of systemic lupus erythematosus (SLE). IRF5 expression is significantly upregulated in SLE patients and upregulation associates with IRF5-SLE risk haplotypes. IRF5 alternative splicing has also been shown to be elevated in SLE patients. Given that human IRF5 exists as multiple alternatively spliced transcripts with distinct function(s), it is important to determine whether the IRF5 transcript profile expressed in healthy donor immune cells is different from that expressed in SLE patients. Moreover, it is not currently known whether an IRF5-SLE risk haplotype defines the profile of IRF5 transcripts expressed. Using standard molecular cloning techniques, we identified and isolated 14 new differentially spliced IRF5 transcript variants from purified monocytes of healthy donors and SLE patients to generate an IRF5 variant transcriptome. Next-generation sequencing was then used to perform in-depth and quantitative analysis of full-length IRF5 transcript expression in primary immune cells of SLE patients and healthy donors by next-generation sequencing. Evidence for additional alternatively spliced transcripts was obtained from de novo junction discovery. Data from these studies support the overall complexity of IRF5 alternative splicing in SLE. Results from next-generation sequencing correlated with cloning and gave similar abundance rankings in SLE patients thus supporting the use of this new technology for in-depth single gene transcript profiling. Results from this study provide the first proof that 1) SLE patients express an IRF5 transcript signature that is distinct from healthy donors, 2) an IRF5-SLE risk haplotype defines the top four most abundant IRF5 transcripts expressed in SLE patients, and 3) an IRF5 transcript signature enables clustering of SLE patients with the H2 risk haplotype.

Indexed as

Alternative SplicingFemaleGene Expression ProfilingGene Expression RegulationHaplotypesHigh-Throughput Nucleotide SequencingHumansInterferon Regulatory FactorsLupus Erythematosus, SystemicMiddle AgedMonocytesPolymorphism, Single NucleotideRisk FactorsRNAInterferon Regulatory FactorsIRF5 protein, humanRNA

Identifiers

PMID23349905
PMCPMC3548774
OpenAlexW2046530746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.